Genes · 2020 · 16 citations · 25 references
Life SciencesGeneticsOncologyCancer GeneticsHuman GeneticsMolecular OncologyGermline Cancer PredispositionGermline Cancer SusceptibilityGermline Variant AnalysisHereditary Cancer SyndromesHereditary Gynecologic Cancer SyndromesVariant ClassificationBrca MutationsFamilial Breast CancerFamilial Cancer RiskFamilial Cancer SyndromesGermline Cancer Predisposition SyndromesGermline Variant ClassificationInherited Cancer Predisposition GenesPathogenic Germline Variants
Hereditary breast and ovarian cancers are mainly linked to variants in BRCA1/2 genes. Recently, data has shown that identification of BRCA variants has an immediate impact not only in cancer prevention but also in targeted therapeutic approaches. This prospective observational study characterized the overall germline BRCA variant and variant of uncertain significance (VUS) frequency and spectrum in individuals affected by breast (BC) or ovarian cancer (OC) and in healthy individuals at risk by sequencing the entire BRCA genes. Of the 363 probands analyzed, 50 (13.8%) were BRCA1/2 mutated, 28 (7.7%) at BRCA1 and 23 (6.3%) at BRCA2 gene. The variant c.5266dupC p.(Gln1756Profs) was the most frequent alteration, representing 21.4% of the BRCA1 variants and 12.0% of all variants identified. The variant c.6313delA p.(Ile2105Tyrfs) of BRCA2 was the most frequent alteration observed in 6 patients. Interestingly, two new variants were identified in BRCA2. In addition, 25 different VUS were identified; two were reported for the first time in BRCA1 and two in BRCA2. The number of triple-negative BCs was significantly higher in patients with the pathogenic BRCA1/2-variant (36.4%) than in BRCA1/2 VUS (16.0%) and BRCA1/2 wild-type patients (10.7%) (p < 0.001). Our study reveals that the overall frequency of BRCA germline variants in the selected high-risk Italian population is about 13.8%. We believe that our results could have significant implications for preventive strategies for unaffected BRCA-carriers and effective targeted treatments such as PARP inhibitors for patients with BC or OC.
25
Sue Richards, Nazneen Aziz, Sherri J. Bale et al. · Genetics in Medicine · 2015 · 32.2K citations · Full text
Aron Goldhirsch, Eric P. Winer, Alan S. Coates et al. · Annals of Oncology · 2013 · 3.7K citations · Full text
Medicine, Oncology, Breast Oncology +10
HGVS Recommendations for the Description of Sequence Variants: 2016 Update
Johan T. den Dunnen, Raymond Dalgleish, Donna Maglott et al. · Human Mutation · 2016 · 1.7K citations · Full text